Exegiline is developing a novel oral drug, MT-31, for the treatment of the symptoms related to Alzheimer’s Disease. MT-31 structure combines Rivastigmine (Exelon) with Rasagiline’s (Azilect) propargyl moiety having unique beneficial properties. MT-31, its derivatives and indication, are protected by a recently granted US and EP patents.
Company Details
- Employees
- 1
- Industry
- Pharmaceutical Manufacturing
- NAICS
-
Pharmaceutical and Medicine ManufacturingMedicinal and Botanical ManufacturingPharmaceutical Preparation ManufacturingIn-Vitro Diagnostic Substance ManufacturingBiological Product (except Diagnostic) Manufacturing
- Website
- http://www.Exegiline.com
- Keywords
- ELDA AI.
Exegiline Questions
Exegiline's website is http://www.Exegiline.com
Exegiline's LinkedIn profile is https://www.linkedin.com/company/exegiline
Exegiline has
1 employees.
View email and phone details for 1
employees at Exegiline.
Exegiline's industry is
Pharmaceutical Manufacturing
Exegiline's top competitors are
Innereye,
Cogme,
Recallcue,
Neurohelp,
Modulight Biotherapeutics,
Elda Ai,
Cogaid,
Neurogenesis Bio Inc.,
Novotalk,
Topicx.
Exegiline's categories are Pharmaceutical Manufacturing
